12:00 AM
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Picoplatin: Additional Phase II data

Additional data from a Phase II trial in 101 chemotherapy-naïve patients showed that IV picoplatin resulted in similar anti-tumor activity as did oxaliplatin, but with significantly less neurotoxicity. Median PFS was 6.8 months in the picoplatin arm (n=51) vs. 7 months...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >